UK MHRA explains policy on naming of medicinal products
This article was originally published in SRA
The UK Medicines and Healthcare products Regulatory Agency has for the first time issued guidance explaining its policy on naming of medicinal products1.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.